DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

DBV Technologies submitted a Biologics License Application (BLA) to the FDA for VIASKIN® Peanut Patch, a non-invasive epicutaneous immunotherapy treatment for peanut allergies in children aged 4-7 years. The submission is supported by positive results from the VITESSE Phase 3 clinical trial involving 654 children, the largest immunotherapy trial for this population. DBV has requested Priority Review status.